In addition, RCE activities against PD-1/PD-L1 PPI were evaluated based on in vitro assays by utilizing human recombinant proteins and human cell lines, therefore, we selected the hPD-L1 expressing MC38 tumor model for testing the in vivo efficacy of RCE (Figure 2). The gene discussed is CD274; the disease is neoplasm.